Jasper Therapeutics KOL Event on Briquilimab: A Monoclonal Antibody with Potential to Treat Chronic Spontaneous Urticaria
About The Event
Join Jasper Therapeutics for a virtual KOL event, featuring Jeffrey V. Ravetch, MD, PhD (The Rockefeller University), Stephen J. Galli, MD (Stanford Medicine), and Prof. Dr. med. Marcus Maurer (Charité – Universitätsmedizin Berlin) who will discuss the unmet medical need and current treatment landscape for patients suffering from chronic spontaneous urticaria, along with the potential for briquilimab to provide an effective treatment solution.
Briquilimab is a monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117 that is being investigated as a therapeutic for chronic mast cell diseases such as chronic urticaria.
A live question and answer session with Jasper Management will follow the formal presentations.